Summary:
- The Canadian Agency for Drugs and Technologies in Health (CADTH) has issued a final positive recommendation for the public reimbursement of lecanemab (Leqembi) for patients with early-stage Alzheimer’s disease.
- Lecanemab is a monoclonal antibody that targets amyloid-beta plaques in the brain, representing a significant scientific advancement in disease-modifying therapies for neurodegenerative conditions.
- The recommendation acknowledges the drug's clinical efficacy in slowing cognitive decline, contingent on specific criteria regarding disease severity and the availability of diagnostic infrastructure for confirmation of amyloid pathology.